Matricelf

Company Overview

Snapshot

Founded in April 2019, Matricelf operates with 11–50 employees. The company has raised over $10 million across 4 funding rounds from 2 investors. A significant milestone was achieved in June 2021 when Matricelf became publicly listed on the TASE.

Business overview

Matricelf is a Health Tech & Life Sciences company focused on regenerative medicine. It develops a personalized platform for autologous engineered tissue, utilizing a proprietary decellularization process to create thermo-responsive hydrogels and reprogrammed induced pluripotent stem cells (iPSCs). This technology is designed to differentiate into desired functional tissues, aiming to treat various medical conditions including spinal cord injuries, age-related macular degeneration, Parkinson's disease, and myocardial infarction. The company operates within the Pharma & Medical Biotechnology sector, specifically in Biomaterials & Tissue Engineering, serving healthcare providers, biotechnology, and pharmaceutical industries.

Strategic signal

In June 2026, Matricelf advanced towards its first-in-human trial by initiating a GMP manufacturing program and successfully completing a GLP safety study for its personalized engineered tissue implants for spinal cord injury. This signals strong progress in the company's clinical development pipeline and validates its regenerative medicine platform, indicating a potential near-term transition to human trials and significant de-risking for investors.

Company Intelligence Q&A

What is Matricelf's core technology?

Matricelf's core technology involves a proprietary decellularization process that separates stromal cells and extracellular matrix (ECM) from a patient's omental biopsy. This allows for the production of a thermo-responsive hydrogel and the reprogramming of stromal cells into induced pluripotent stem cells (iPSCs), which are then differentiated into functional tissue for regenerative medicine applications.

When did Matricelf become a public company?

Matricelf became publicly listed on the TASE in June 2021.

What recent strategic collaborations has Matricelf announced?

In March 2026, Matricelf entered a strategic collaboration with Japan's CiRA Foundation to advance next-generation regenerative manufacturing. Additionally, in March 2026, Matricelf entered a strategic collaboration with Sheba Medical Center to advance its first-in-human clinical program in spinal cord injury.

What recent progress has Matricelf made regarding its spinal cord implant?

In June 2026, Matricelf advanced toward its first-in-human trial by initiating a GMP manufacturing program and successfully completing a GLP safety study for its personalized engineered tissue implants for spinal cord injury. In March 2026, Matricelf also reported positive RNA sequencing results demonstrating a promising safety profile of its personalized spinal cord implant.

Has Matricelf received any recent industry recognition?

In March 2026, Matricelf was named the Most Innovative Company of 2026 at Advanced Therapies Week in San Diego.